EQUITY BANCSHARES INC
For the period ended Dec 31, 2024. Filed Mar 7, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 7, 2025
EQBK$49.21-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(Dollar amounts in thousands, except share and per share data)
| Common Stock · Accumulated | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SharesOutstanding · Amount · AdditionalPaid-InCapital · RetainedEarnings · OtherComprehensiveIncome (Loss) · TreasuryStock · TotalStockholders’Equity | ||||||||||||
| Balance at December 31, 2021 | 16,760,115 | $203 | $478,862 | $88,324 | $1,776 | $(68,534) | $500,631 | |||||
| Net income | — | — | — | 57,688 | — | — | 57,688 | |||||
| Other comprehensive income/(loss), net of tax effects | — | — | — | — | (115,287) | — | (115,287) | |||||
| Cash dividends - common stock, $0.36 per share | — | — | — | (5,801) | — | — | (5,801) | |||||
| Dividend equivalents - restricted stock units, $0.36 per share | — | — | — | (116) | — | — | (116) | |||||
| Stock-based compensation, see Note 17 | 624 | — | 3,325 | — | — | — | 3,325 | |||||
| Common stock issued upon exercise of stock options | 102,309 | 1 | 2,010 | — | — | — | 2,011 | |||||
| Common stock issued under stock-based incentive plans | 69,089 | 1 | — | — | — | — | 1 | |||||
| Common stock issued under employee stock purchase plan | 28,829 | — | 792 | — | — | — | 792 | |||||
| Treasury stock purchases | (1,030,854) | — | — | — | — | (33,186) | (33,186) | |||||
| Balance at December 31, 2022 | 15,930,112 | $205 | $484,989 | $140,095 | $(113,511) | $(101,720) | $410,058 | |||||
| Net income (loss) | — | — | — | 7,821 | — | — | 7,821 | |||||
| Other comprehensive income/(loss), net of tax effects | — | — | — | — | 55,591 | — | 55,591 | |||||
| Cash dividends - common stock, $0.44 per share | — | — | — | (6,819) | — | — | (6,819) | |||||
| Dividend equivalents - restricted stock units, $0.44 per share | — | — | — | (91) | — | — | (91) | |||||
| Stock-based compensation, see Note 17 | — | 3,213 | — | — | — | 3,213 | ||||||
| Common stock issued upon exercise of stock options | 12,829 | — | 203 | — | — | — | 203 | |||||
| Common stock issued under stock-based incentive plan | 137,820 | 2 | (2) | — | — | — | — | |||||
| Common stock issued under employee stock purchase plan | 32,056 | — | 784 | — | — | — | 784 | |||||
| Treasury stock purchases | (669,166) | — | — | — | — | (17,900) | (17,900) | |||||
| Balance at December 31, 2023 | 15,443,651 | $207 | $489,187 | $141,006 | $(57,920) | $(119,620) | $452,860 | |||||
| Net income (loss) | — | — | — | 62,621 | — | — | 62,621 | |||||
| Other comprehensive income/(loss), net of tax effects | — | — | — | — | 2,739 | — | 2,739 | |||||
| Cash dividends - common stock, $0.54 per share | — | — | — | (8,575) | — | — | (8,575) | |||||
| Dividend equivalents - restricted stock units, $0.54 per share | — | — | — | (132) | — | — | (132) | |||||
| Stock-based compensation, see Note 17 | — | 4,048 | — | — | — | 4,048 | ||||||
| Common stock issued upon exercise of stock options | 147,777 | 1 | 3,505 | — | — | — | 3,506 | |||||
| Common stock issued under stock-based incentive plan | 102,066 | 1 | (1) | — | — | — | — | |||||
| Common stock issued under employee stock purchase plan | 29,465 | — | 726 | — | — | — | 726 | |||||
| Common stock issued with private placement, net of offering costs | 2,067,240 | 21 | 86,959 | — | — | — | 86,980 | |||||
| Treasury stock purchases | (362,573) | — | — | — | — | (11,855) | (11,855) | |||||
| Balance at December 31, 2024 | 17,427,626 | $230 | $584,424 | $194,920 | $(55,181) | $(131,475) | $592,918 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.